Dejager, Sylvie

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

Bruckert, E., Hayem, G., Dejager, S., Yau, C., & Bégaud, B. (2005) · Cardiovascular Drugs and Therapy

Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug Reactions

Cited by 1,226

Toward Defining the Threshold Between Low and High Glucose Variability in Diabetes

Monnier, L., Colette, C., Wojtusciszyn, A., Dejager, S., Renard, E., Molinari, N., & Owens, D. R. (2017) · Diabetes Care

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 390

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes

Pi-Sunyer, F. X., Schweizer, A., Mills, D., & Dejager, S. (2007) · Diabetes Research and Clinical Practice

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 312

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes

Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 255

Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia.

Dejager, S., Bruckert, E., & Chapman, M. (1993) · Journal of Lipid Research

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 237